28-gene thrombosis and coagulation panel for inherited bleeding and clotting disorders.
A 28-gene panel for inherited thrombophilias and coagulation disorders, including Factor V Leiden, Prothrombin G20210A, and protein C/S/antithrombin deficiencies.
GenDG §10
This is a predictive genetic test.
The order page will ask you to either book counseling or waive counseling in writing per German GenDG §10. Your choice is fully documented and accessible at any time.
HOW IT WORKS
How it works.
01
Easy at-home test
Order in three clicks, no login. Kit ships from Berlin within 5 working days.
02
Get your report and personalized action plan
Follow the guided sample collection. Your AI-interpreted clinical report arrives by secure email.
03
Consult with professionals and retest
Discuss findings with your physician or our medical geneticist; retest as your interventions evolve.
WHICH PART OF YOUR BODY
Which part of your body.
Blood clotting
Lungs (pulmonary embolism)
Legs (deep vein thrombosis)
Brain (stroke)
WHAT THIS PANEL ANSWERS
What this panel answers.
Do you carry inherited variants that raise your risk of forming dangerous blood clots?
WHAT CHANGES IF A FINDING IS IDENTIFIED
What changes if something is found.
01Factor V Leiden, prothrombin, protein C and S deficiency, and antithrombin deficiency carriers receive concrete travel and surgical precautions -- compression stockings on long-haul flights, prophylactic anticoagulation around major surgery, hospitalization, and pregnancy.
02Hormonal contraception and hormone-replacement decisions are individualized with your physician.
03Family cascade testing identifies relatives at the same risk.
Pathway references
GenDG §7
GENES ANALYZED
What is analyzed.
Atlas analyzes each gene in its entirety -- not just hotspot regions -- against current clinical literature. Findings are reviewed by a board-certified medical geneticist before release.
PRV03
Thrombosis & Coagulation Disorders
28 genes
A 28-gene panel covering inherited clotting and bleeding disorders. Includes the common thrombophilia variants (Factor V Leiden in F5, prothrombin in F2), the protein C/S/antithrombin pathway, von Willebrand factor, and the hemophilia A/B factor genes.
Clinical areas covered
—Factor V Leiden and prothrombin variants
—Protein C / protein S deficiency
—Antithrombin deficiency
—Von Willebrand disease
—Hemophilia A and B
—Platelet-function disorders
Analyzed genes -- 28 genesShow all genes →Hide genes ↑
ADAMTS13
F10
F11
F12
F13A1
F13B
F2
F5
F7
F8
F9
GFI1B
GP1BA
GP1BB
GP6
GP9
HRG
ITGA2B
ITGB3
LMAN1
MCFD2
NBEAL2
PROC
PROS1
SERPINC1
SERPIND1
SERPINF2
VWF
Limitations
!F8 intronic inversions are not detected by the standard short-read sequencing assay -- if hemophilia A is clinically suspected, an inversion-specific test is required.
Gene list per CeGaT PRV03 (2026-05).
WHY THIS MATTERS
Why early knowledge matters.
PRV03
Thrombosis & Coagulation Disorders
Inherited thrombophilia substantially raises the risk of deep-vein thrombosis, pulmonary embolism, and stroke -- particularly under hormonal contraception, pregnancy, surgery, immobilization, or long-haul travel. Knowing your status can change which contraceptive a physician prescribes and what perioperative prophylaxis is used.
RESULT INTERPRETATION
How findings are reported.
Every Atlas predictive report uses the same five-outcome framework so you and your physician can read it the same way each time.
01
Pathogenic variant
Increased disease risk. The report includes an individualized prevention plan and a recommendation to discuss next steps with a physician or medical geneticist.
02
Likely pathogenic variant
Probable disease association. Preventive monitoring is typically justified; the strength of evidence is documented in the report.
03
Variant of uncertain significance (VUS)
Reported but not currently actionable. A VUS may be reclassified over time as new evidence accumulates -- Atlas does not act on VUS findings without specialist review.
04
No relevant variant in this panel
No pathogenic or likely-pathogenic variant was identified in the analyzed genes. This does not eliminate all genetic risk -- only the genes in this panel were assessed.
05
Family implications
When an actionable variant is found, cascade testing of first-degree relatives is typically recommended -- a decision made together with a counselor.
Module-specific implications
PRV03
Thrombosis & Coagulation Disorders
—A confirmed thrombophilia variant is typically discussed with a hematologist or human geneticist -- not all carriers need anticoagulation, and decisions are context-specific.
—Pregnancy, surgery, and hormonal therapy are common triggers where the finding changes management.
Predictive genetic testing in Germany requires consultation with a physician qualified in human genetics under §7 of the GenDG (Arztvorbehalt). Atlas Counseling provides this before and after the test. When an actionable finding has implications for relatives, your counselor will discuss cascade testing -- not Atlas alone.
CLINICAL LIMITATIONS
What this test does not do.
Not a diagnosis of active disease
A variant indicates predisposition. It does not confirm a condition is currently present.
Does not replace screening or routine care
Imaging, lab work, and physical examination remain part of clinical care. Atlas results inform them; they do not substitute for them.
Not all risk is genetic
Environment, behavior, age, and chance contribute to most common conditions. A genetic test reads one input.
A negative result does not eliminate risk
Only the genes on the panel were analyzed. Variants in other genes, in non-coding regions, and outside the assay's technical scope are not assessed.
Clinical decisions remain with your physician
Atlas reports are designed to be reviewed with a physician or medical geneticist. We do not recommend acting on a finding without that conversation.
GenDG §7
Predictive panels on this page are GenDG §7 Arztvorbehalt: counseling with a qualified human-genetics physician is required before and after the test. Atlas Counseling is included in the order flow.
Ready to start? €390 · 3–4 weeks after sample arrival